The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
|Articles|March 9, 2021
Biologics Contract Development and Manufacturing Services
Author(s)Emergent BioSolutions
Contract development and manufacturing (CDMO) services with support for mammalian, microbial, viral, plasma, and gene therapy.
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Since 1998, Emergent BioSolutions has been a go-to source for solving some of the most complex and critical challenges in public health. From initial R&D and clinical studies to formulation, manufacturing and packaging, our experienced CDMO team at Emergent is ready to serve as your trusted guide from molecule to market.
Emergent BioSolutions
Related to this article
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
Trending on Pharmaceutical Technology
1
AAPS PharmSci 360 2026: IND-Enabling Studies vs Animal Data
2
AI Formulation: Regulators Want Data
3
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
4
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
5